Navigation Links
New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering
Date:6/16/2008

Data published in the Journal of the American Society of Hypertension

demonstrate that early blockade of angiotensin II reversed vascular

hypertrophy

PARSIPPANY, N.J., June 16 /PRNewswire/ -- A new study published in the current Journal of the American Society of Hypertension demonstrates that the hypertension treatment olmesartan medoxomil was effective in reversing the narrowing of the arteries that occurs in patients with hypertension. The study, titled VIOS (Vascular Improvement with Olmesartan medoxomil Study) was a one-year, exploratory study that evaluated the effects of an angiotensin receptor blocker (olmesartan medoxomil) vs. a beta-blocker (atenolol) on vascular function and structure in patients with Stage 1 hypertension, independent of the blood pressure lowering effects of these agents.(1)

In the VIOS trial, olmesartan medoxomil, through early blockade of angiotensin II, improved the structure abnormalities of resistance arteries in patients with hypertension as measured by arterial wall to lumen ratio (W/L), returning arterial architecture to normal levels after one year of treatment. This protective effect was not seen with the comparator agent in the study, atenolol.(2) Olmesartan medoxomil is marketed in the United States by Daiichi Sankyo, Inc., as BENICAR(R). BENICAR and BENICAR HCT(R) (olmesartan medoxomil/hydrochlorothiazide) are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents. BENICAR HCT is not indicated for initial therapy. BENICAR and BENICAR HCT have not been FDA approved for other indications such as end organ disease or other hypertension related morbidity.

"We believe the VIOS data add to the growing evidence for the role of angiotensin receptor blockers in preventing or reversing vascular damage at many stages during this disease process," said Carlos M. Ferrario, M.D., one of the study's lead inve
'/>"/>

SOURCE Daiichi Sankyo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study
2. NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
3. Pharmaxis Long-Term Safety Study of Bronchitol Completes
4. Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers Diarrhea Vaccine
5. The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxters Cell-Based Pandemic, Avian Flu Vaccine
6. Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
7. Genmab A/S - Company Announcement Ofatumumab in Subcutaneous Study in Rheumatoid Arthritis Summary: Subcutaneous Administration of Ofatumumab Investigated in Phase I/II Study
8. Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes
9. Results From One-Year Study Suggest Advair(R) Provides Important Benefits for African American Patients With Asthma
10. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
11. Banner Alzheimers Institute and Sun Health Research Institute Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , Oct. 1, 2014 Trovagene, Inc., ... announced today that Eli Diamond , MD, ... Center (MSK), presented clinical data from an ongoing ... monitoring platform for the determination of oncogene mutational ... biopsy.  The results were presented to both treating ...
(Date:10/1/2014)... MARCOS, Texas , Oct. 1, 2014 /PRNewswire/ ... it is scaling volume production of photoactive quantum ... power technologies . While offering numerous advantages for ... of producing large quantities of quantum dots with ... until now kept them from commercial utilization and ...
(Date:10/1/2014)... Oct. 1, 2014  CVS Health is thanking its ... role in changing the way health care is delivered ... the Company,s retail pharmacies, mail service pharmacies and specialty ... our company name to CVS Health to reflect our ... the innovations needed to shape the future of health," ...
Breaking Medicine Technology:Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 2Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 4Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 3CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 2CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 3
... 2012 i-Path Media LLC, a pharmaceutical marketing ... with their clients, received national certification as a ... Organization-New York Certification Committee, a regional certifying partner ... WBENC,s national standard of certification is ...
... Jan. 16, 2012  Palatin Technologies, Inc. (NYSE Amex: ... targeted, receptor-specific peptide therapeutics for the treatment of ... potential, today announced that Dr. Carl Spana, President ... Noble Financial Capital Markets, Eighth Annual Equity Conference.  ...
Cached Medicine Technology:Palatin Technologies to Present at BOCEMb, Noble Financial Capital Markets' Eighth Annual Equity Conference 2
(Date:10/1/2014)... Farmington Company today announced it has ... visual identity helping brokers, consultants and companies to ... create greater benefit communication synergies. They unveiled a ... customers to better leverage Farmington Company’s industry-tested experience ... the rebrand is the refreshed tagline: For the ...
(Date:10/1/2014)... Beverly Hills licensed Clinical Psychologist and nationally ... years of private practice in her Beverly Hills office ... greater joy and fulfillment in their relationships. Dr. Mojas ... suggestions for anyone who suspects they are in a ... or not, it’s not always easy to know when ...
(Date:10/1/2014)... NJ (PRWEB) October 01, 2014 Diet Doc ... their intentions to lose weight and their dieting attempts could ... fatty foods. Including hormone diet treatments into their ... allows patients to see fast and effective weight loss results, ... begin forming healthy habits to maintain their weight for the ...
(Date:10/1/2014)... Scientists at the University of Western Australia ... system proteins has the power to knock out mesothelioma ... the new study on their website. Click here ... the UWA School of Pathology and Laboratory Medicine administered ... mesothelioma with promising results. , “A timed triple ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Nordic ... benefit a very special cause. The campaign—“Buy One ... for Paws for Veterans, a nonprofit organization that ... also rescuing shelter dogs that would otherwise face ... featured products will support monthly donations of Nordic ...
Breaking Medicine News(10 mins):Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4Health News:New Mesothelioma Study Says Mice Cured by Immuntherapy “Cocktail”, Reports Surviving Mesothelioma 2Health News:Nordic Naturals® Inspires Support for Paws for Veterans -- ‘Buy One Bottle. Help Two Heroes.’ Initiative Kicks Off October 1 2
... , ATLANTA and PHILADELPHIA, ... Technology, collaborating with pediatric cardiologists and surgeons at The ... virtual surgery that allows heart surgeons to view the ... cardiac magnetic resonance images of a patient,s specific anatomy, ...
... , , NIAGARA ... Pacific Corporation,s (Nasdaq: APFC ) wholly-owned in-space propulsion ... monopropellant engines, with a 30+ year history of successful space ... NASA,s Lunar Reconnaissance Orbiter (LRO) and Lunar Crater Observation and ...
... ... Technology for its Passport Assets Application Enabling Its Customers to Improve System Efficiency, Improve ... ... ASAP Systems today announced the release of its mobile RFID technology for their ...
... , , , ... device franchise, announced today the launch of eMed-Alert, a next-generation personal assistance ... in an emergency. With more than 11 million Americans age 65 ... their independence. , , "As baby ...
... , SOMERSET, N.J., Aug. 11 ... healthcare and administrative staffing services, will announce its third quarter financial results ... before the market opens. TeamStaff will host a conference call for ... Interested parties may participate in the call by dialing (877) ...
... PRINCETON, N.J., Aug. 11 Ranbaxy Pharmaceuticals Inc. (RPI), a ... that RLL has received final approval from the U.S. Food ... 25 mg (base), and 50 mg (base). The Office ... the Ranbaxy formulations to be bioequivalent and have the same ...
Cached Medicine News:Health News:MRI Simulation of Blood Flow Helps Plan Child's Heart Surgery 2Health News:MRI Simulation of Blood Flow Helps Plan Child's Heart Surgery 3Health News:MRI Simulation of Blood Flow Helps Plan Child's Heart Surgery 4Health News:MRI Simulation of Blood Flow Helps Plan Child's Heart Surgery 5Health News:AMPAC-ISP Engines Support Key NASA Lunar Missions 2Health News:ASAP Systems Introduces Mobile RFID Technology for its Passport Assets Application Enabling Increase Asset Management Flexibility 2Health News:ASAP Systems Introduces Mobile RFID Technology for its Passport Assets Application Enabling Increase Asset Management Flexibility 3Health News:World's First Emergency Medical Device Franchise Launches eMed-Alert 2Health News:World's First Emergency Medical Device Franchise Launches eMed-Alert 3Health News:TeamStaff, Inc. To Announce Third Quarter Results 2Health News:TeamStaff, Inc. To Announce Third Quarter Results 3Health News:Ranbaxy Receives Final Approval To Market Sumatriptan Succinate Tablets 2
... testing your blood glucose regularly, you want ... possible. Conventional spring-loaded lancet systems often penetrate ... cause painful dilation or tearing of skin ... a precise, linear action that provides greater ...
... Focus from Thermo Labsystems was designed specifically ... Advanced features such as the new fast ... on microvolumes help to define this as ... The new interchangeable handle plate offers a ...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,410-0) or contact custom...
... models cover the range from 2ul to 5000ul. ... Volume lock design prevents inadvertent volume change. ... Whole pipette is autoclavable at 121C(250F). ... polypropylene. Suitable for one-handed operation. Auto ...
Medicine Products: